{"schema_version":"secwatch.filing_event.v1","accession":"0001730430-26-000005","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.024127+00:00","generated_at":"2026-05-16T10:54:21.595503+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M","bullets":["ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.","2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.","Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.","KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.","~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001730430-26-000005","json":"https://secwatch.observer/filing/0001730430-26-000005.json","markdown":"https://secwatch.observer/filing/0001730430-26-000005.md","text":"https://secwatch.observer/filing/0001730430-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/0001730430-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/knsa-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:21.595503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}